Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014

Novartis International AG / Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial

• Final overall survival data from Phase III trial of Afinitor in advanced pancreatic neuroendocrine tumors (pNET)

• Findings on Novartis pipeline compounds that target underlying cause of key diseases, including breast cancer, advanced basal cell carcinoma and melanoma

Basel, September 17, 2014 - Novartis will showcase new data at the European Society for Medical Oncology (ESMO) Congress, September 26-30, 2014 in Madrid, Spain. In keeping with the meeting's focus on "Precision Medicine in Cancer Care," Novartis will feature compounds that target specific pathways and molecular markers involved in cancer.

The Novartis data include new analyses from the pivotal trial evaluating Zykadia(TM) (ceritinib) in ALK+ non-small cell lung cancer (NSCLC), overall survival results from the pivotal trial of the mTOR inhibitor Afinitor^® (everolimus) in advanced pancreatic neuroendocrine tumors (pNET), and updated patient management data for Afinitor in advanced breast cancer. In addition, Novartis will present study results on key pipeline compounds, including data for the Hedgehog inhibitor LDE225 (sonidegib) in advanced basal cell carcinoma, the CDK4/6 inhibitor LEE011 and the BRAF inhibitor LGX818 (encorafenib) in melanoma, the MEK inhibitor MEK162 (binimetinib) in NRAS-mutant melanoma, and PI3K inhibitors BKM120 (buparlisib) and BYL719 (alpelisib) in solid tumors.

"At ESMO 2014 we will present new data on key compounds that demonstrate the breadth of the biological markers we target," said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs. "By understanding what drives different cancers to develop and grow, our clinical program has led to the development of precise therapies for patients with the specific genetic profile targeted by these treatments, enabling us to make a difference for people living with these diseases."

More than 30 abstracts involving Novartis compounds will be presented at ESMO 2014, including[1]:

Compound	Description of study	Abstract number
Ceritinib	Efficacy and Safety of Ceritinib in Patients with Advanced Anaplastic Lymphoma Kinase (ALK)-rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC): An Update of ASCEND-1	Abstract #1295P
Ceritinib	Evaluation of Ceritinib-treated Patients with Anaplastic Lymphoma Kinase rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC) and Brain Metastases in the ASCEND-1 study	Abstract #1293P
Everolimus	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results of a Randomized, Double-blind, Placebo (PBO)-Controlled, Multicenter Phase III Trial (RADIANT-3)	Abstract #1132O
Everolimus + Exemestane	Breast Cancer Treatment with Everolimus and Exemestane for ER+ Women - Results of the 2nd interim analysis of the non-interventional trial BRAWO	Abstract #LBA9
LDE225 (sonidegib)	Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with advanced basal cell carcinoma (BCC)	Abstract #LBA33
LDE225 (sonidegib) + BKM120 (buparlisib)	Dose-escalation study of sonidegib (LDE225) plus buparlisib (BKM120) in patients with advanced solid tumors	Abstract #445O
LEE011 + LGX818 (encorafenib)	Phase Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma	Abstract #1086O
MEK162 (binimetinib)	Overall Survival and Biomarker Results from a Phase 2 Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-mutant Melanoma	Abstract #LBA35
BYL719 (alpelisib)	Phase I study of the PI3Kalpha inhibitor BYL719, as a single agent in patients with advanced solid tumors (aST)	Abstract #451PD

Throughout ESMO 2014, Novartis Oncology will host a dedicated webpage (http://www.novartisoncology.com/ESMO-2014.jsp) that will provide unique insights and perspectives on emerging areas of cancer care and research.